| Filed On | Filing |
|---|---|
| 04 Nov 2026 | 10-Q |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
Received Regenerative Medicine Advanced Therapy (RMAT) Designation from U.S. FDA for TN-401 Gene Therapy for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy |
| 23 Oct 2026 | DEFA14A |
| 23 Oct 2026 | DEF 14A |
| 13 Oct 2026 | PRE 14A |
| 11 Sep 2026 |
Form 4: Ali Faraz, Director
Received 122,000 shares as a grant or award · Granted 732,500 Stock Option (Right to buy) |
| 11 Sep 2026 |
Form 4: Tingley Whittemore, Chief Medical Officer
Received 49,000 shares as a grant or award · Granted 293,000 Stock Option (Right to buy) |
| 24 Aug 2026 | SCHEDULE 13G |
| 17 Aug 2026 |
Form 4: Ali Faraz, Director
Sold 22,232 shares ($15.8K) |
| 17 Aug 2026 |
Form 4: Tingley Whittemore, Chief Medical Officer
Sold 7,424 shares ($5.27K) |
| 17 Aug 2026 | 144 |
| 17 Aug 2026 | 144 |
| 05 Aug 2026 | S-8 |
| 05 Aug 2026 | 10-Q |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
Positive Interim Data Shared in 2Q 2026 from the MyPEAK™-1 and RIDGE™-1 Clinical Trials Each Demonstrated Meaningful Improvements in Key Disease Characteristics |
| 14 Jul 2026 |
Form 3: Hyllengren Eric J, Chief Financial Officer
No securities owned |
| 14 Jul 2026 |
Form 4: Hyllengren Eric J, Chief Financial Officer
Granted 1,650,000 Stock Option (Right to buy) |
| 02 Jul 2026 |
8-K: Termination of a Material Definitive Agreement
On June 29, 2026, Tenaya Therapeutics, Inc. (the “Company”) entered into a Lease Termination Agreement with Terreno Park Union City LLC to terminate the Company’s lease for approximately 94,046 rentable square feet at 33498 Central Avenu... |
| 29 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
On behalf of Tenaya Therapeutics, Inc. (“Tenaya” or the “Company”), I am pleased to invite you to join the Company as Chief Financial Officer, reporting to the Company’s Chief Executive Officer. Your primary work location will be Thousan... |
| 29 May 2026 |
Form 4: Williams R Sanders, Director
Granted 120,000 Stock Option (Right to buy) |
Loading...